ReviewJournal of clinical medicine2023
Sarcoidosis-Related Uveitis: A Review.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- The theory of the inflammatory ecosystem.Science China. Life sciences · 2026Review
- Ocular TB as the only manifestation of TB: diagnostic uncertainty and treatment thresholds.International ophthalmology · 2026Review
- Cognitive bias and clinical acumen in uveitis practice.Indian journal of ophthalmology · 2026Article
- Advanced Multimodal Imaging in Granulomatous Uveitis: From Differential Diagnosis to Treatment Monitoring and Surgical Integration.Journal of clinical medicine · 2026Review
- Hydroxychloroquine in the treatment of sarcoidosis-associated uveitis and idiopathic uveitis.Journal of ophthalmic inflammation and infection · 2026Article
- Dermatological Indicators of Systemic Autoimmune Disease: Clinical Links to Ocular Involvement.Dermatology practical & conceptual · 2026Review
- Diagnostic Factors Associated with Sarcoidosis in Patients Referred for EBUS-TBNA Due to Mediastinal Lymphadenopathy.Advances in respiratory medicine · 2026Article
- Increased Risk of Incident Uveitis Among Patients with Psoriasis: A Nationwide Population-Based Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Review
- Article
- Ophthalmological manifestations in autoimmune diseases: Overcoming diagnostic and therapeutic challenges.World journal of experimental medicine · 2025Review
- Treatment of ocular sarcoidosis. Study of 65 patients from a series of 342 from a university hospital in northern Spain.International ophthalmology · 2025Article
- Chronic Sarcoidosis: Diagnostic Difficulties and Search for New Criteria of Inflammatory Activity (A Case Report and Literature Review).Journal of clinical medicine · 2024Review
- [Position paper of the Austrian Society for Rheumatology and the Austrian Society for Pneumology on the diagnosis and treatment of sarcoidosis 2024].Wiener klinische Wochenschrift · 2024Article
- Increased serum interferon activity in sarcoidosis compared to that in tuberculosis: Implication for diagnosis?Heliyon · 2024Article
- A serum B-lymphocyte activation signature is a key distinguishing feature of the immune response in sarcoidosis compared to tuberculosis.Communications biology · 2024Article
- A Case of Unilateral Vision Loss Due to Optic Disc Infiltration by Sarcoidosis.Journal of general internal medicine · 2024Article
- Choroidal manifestations of non-ocular sarcoidosis: an enhanced depth imaging OCT study.BMC ophthalmology · 2024Article
- Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.Frontiers in immunology · 2023Article
- Ocular Sarcoidosis: Contemporary Insights and Future Directions.Romanian journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is an inflammatory disease that involves the eyes in 10-55% of cases, sometimes without systemic involvement. All eye structures can be affected, but uveitis is the most common ocular manifestation and causes vision loss. The typical ophthalmological appearance of these uveitis is granulomatous (in cases with anterior involvement), which are usually bilateral and with synechiae. Posterior involvement includes vitritis, vasculitis and choroidal lesions. Tuberculosis is a classic differential diagnosis to be wary of, especially in people who have spent time in endemic areas. The diagnosis is based on histology with the presence of non-caseating epithelioid granulomas. However, due to the technical difficulty and yield of biopsies, the diagnosis of ocular sarcoidosis is often based on clinico-radiological features. The international criteria for the diagnosis of ocular sarcoidosis have recently been revised. Corticosteroids remain the first-line treatment for sarcoidosis, but up to 30% of patients require high doses, justifying the use of corticosteroid-sparing treatments. In these cases, immunosuppressive treatments such as methotrexate may be introduced. More recent biotherapies such as anti-TNF are also very effective (as they are in other non-infectious uveitis etiologies).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.